Does the Hyper IgM Phenotype Affect Prognosis in Ataxia Telangiectasia?

Objective: To evaluate the characteristics of the patients who were followed-up with the diagnosis of ataxia telangiectasia (AT) and to assess the relationship between the hyper IgM (HIGM) phenotype and their prognosis.Materials and Methods: From 2007 to 2019, the study included 68 patients aged 3-35 years who were followed-up with the diagnosis of AT. We retrospectively evaluated the clinical and immunological characteristics and follow-up results. Results: There were 36 girls and 32 boys with a median follow-up of 10 years (1-12 years). The most common complaints upon admission were unsteady walk in 87%, infection in 6%, presence of a family history in 6%, and intracranial mass in 1%. The marriage was consanguineous in 85% of the parents. Ataxia was seen in 100% of the patients, telangiectasia in 97%, and immune deficiency in 88%. Bronchiectasis was observed in 23.5% of the patients, chronic diarrhea in 19%, lymphoproliferation in 15%, malignancy in 10%, autoimmunity in 10%, liver failure in 6%, and granulomatous skin lesions in 6%. Thirteen patients (19%) died during follow-up. The HIGM phenotype was identified in 31% of the patients. Recurrent upper and lower respiratory tract infections (p=0.004 and p<0.0001, respectively), liver failure (p=0.005), and autoimmune diseases (p=0.023) were significantly higher in the HIGM (+) group than the HIGM (-) group. Life expectancy was shorter in the HIGM (+) group with 14 ± 0.73 years (CI 95% 12.55-15.44) compared to the HIGM (-) group with 18 ± 1.64 years (CI 95% 14.77-21.22) (p=0.054).Conclusion: During the early childhood period and before the characteristic findings of AT develop, the patients might present at a hospital with infections, autoimmunity, lymphoproliferation, or malignancy. Physical examination, high alpha-fetoprotein (AFP) levels and immunological testing provide important data for the correct diagnosis. The HIGM phenotype aggravates the clinical course of the disease resulting in fatalities at an earlier age and at a higher rate.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Boder E, Sedgwick RP. A familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection: A preliminary report on 7 children, an autopsy, and a case history. Univ Southern Calif Med Bull 1957; 9:15-28.
2. Gatti RA, Berkel I, Boder E, Braedt G, Charmley P, Concannon P, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-2 3. Nature 1988;336:577-80.
3. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, et al. A single ataxia-telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268:1749-53.
4. Savitsky K, Sfez S, Tagle D, Ziv Y, Sartiel A, Collins FS, et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 1995;4:2025-32.
5. Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst) 2004;3(8-9):1187-96.
6. Moin M, Aghamohammadi A, Kouhi A, Tavassoli S, Rezaei N, Ghaffari SR, et al. Ataxia-telangiectasia in Iran: Clinical and laboratory features of 104 patients. Pediatr Neurol 2007;37(1):21-8.
7. van Os NJH, Jansen AFM, van Deuren M, Haraldsson A, van Driel NTM, Etzioni A, et al. Ataxia-telangiectasia: Immunodefciency and survival. Clin Immunol 2017; 178:45-55.
8. Bredemeyer AL, Huang CY, Walker LM, Bassing CH, Sleckman BP. Aberrant V(D)J recombination in ataxia telangiectasia mutated-deficient lymphocytes is dependent on nonhomologous DNA end joining. J Immunol 2008;15;181(4):2620-5.
9. Roifman CM, Gelfand EW. Heterogeneity of the immunological deficiency in ataxia-telangiectasia: Absence of a clinical-pathological correlation. Kroc Found Ser 1985;19:273-85.
10. Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, Carson KA, Lederman HM. Immunodeficiency and infections in ataxia telangiectasia. J Pediatr 2004;144(4):505-11.
11. Ghiasy S, Parvaneh L, Azizi G, Sadri G, Zaki Dizaji M, Abolhassani H, et al. The clinical significance of complete class switching defect in Ataxia telangiectasia patients. Exp Rev Clin Immunol 2017;13:499-505.
12. Noordzij JG, Wulffraat NM, Haraldsson A, Meyts I, van’t Veer LJ, Hogervorst FB, et al. Ataxia-telangiectasia patients presenting with hyperIgM syndrome. Arch Dis Child 2009;94:448-9.
13. Aghamohammadi A, Imai K, Moazzami K, Abolhassani H, Tabatabaeiyan M, Parvaneh N, et al. Ataxia-telangiectasia in a patient presenting with hyperimmunoglobulin M syndrome. J Investig Allergol Clin Immunol 2010;20:442-5.
14. Etzioni A, Ochs HD. The hyper IgM syndrome an evolving story. Pediatr Res 2004;56:519-25.
15. Alyasin S, Esmaeilzadeh H, Ebrahimi N, Nabavizadeh SH, Nemati H. Clinical presentation of ataxia-telangiectasia. Arch Iran Med 2019;22(12):682-6.
16. Bodemer C, Sauvage V, Mahlaoui N, Cheval J, Couderc T, Leclerc-Mercier S, et al. Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with primary immunodeficiency. Clin Microbiol Infect 2014;20(10):O656-63.
17. Slack J, Albert MH, Balashov D, Belohradsky BH, Bertaina A, Bleesing J, et al. Outcome of hematopoietic cell transplantation for DNA doublestrand break repair disorders. J Allergy Clin Immunol 2018;141:322.e10-8.
18. Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 1986;39(5):573-83.
19. Sanal O, Gerçeker FO, Yel L, Ersoy F, Tezcan I, Berkel I, et al. Impaired IgG antibody production to pneumococcal polysaccharides in patients with ataxia-telangiectasia. J Clin Immunol 1999;19(5):326-34.
20. Akturk H, Sutcu M, Somer A, Piskin S, Acar M, Ozmen M, et al. Ataxia telangiectasia in Turkey: Multisystem involvement of 91 patients. World J Pediatr 2017;13(5):465-71.
21. Azarsız E, Karaca NE, Gunaydın NC, Gulez N, Ozturk C, Aksu G, et al. Do elevated serum IgM levels have to be included in probable diagnosis criteria of patients with ataxia-telangiectasia? Int J Immunopathol Pharmacol 2014;27(3):421-7.
22. Mandola AB, Reid B, Sirror R, Brager R, Dent P, Chakroborty P, et al. Ataxia telangiectasia diagnosed on newborn screening-case cohort of 5 years’ experience. Front Immunol 2019;10:2940.
23. Amirifar P, Ranjouri MR, Yazdani R, Abolhassani H, Aghamohammadi A. Ataxia telangiectasia: A review of clinical features and molecular pathology. Pediatr Allergy Immunol. 2019;30(3):277-88.
24. Chopra C, Davies G, Taylor M, Anderson M, Bainbridge S, Tighe P, McDermott EM. Immune deficiency in ataxia-telangiectasia: A longitudinal study of 44 patients. Clin Exp Immunol 2014;176 (2):275-82.
25. Nissenkorn A, Shraga LY, Levi YB, Lahad A, Sarouk I, Moses DM. Endocrine abnormalities in ataxia telangiectasia: Findings from a national cohort. Pediatr Res 2016;79(6):889-94.
26. Chiam LY, Verhagen MM, Haraldsson A, Wulffraat N, Driessen GJ, Netea MG, et al. Cutaneous granulomas in ataxia telangiectasia and other primary immunodeficiencies: Reflection of inappropriate immune regulation? Dermatology 2011;223:13-9.
27. Carranza D, Rusillo ST, Pérez GC, Jimenez EB, López MM, García-Pérez JL, et al. Reconstitution of the ataxia-telangiectasia cellular phenotype with lentiviral vectors. Front Immunol2018;9:2703.
28. Ghosh S, Schuster FR, Binder V, Niehues T, Baldus SE, Seiffert P, et al. Fatal outcome despite full lympho-hematopoietic reconstitution after allogeneic stem cell transplantation in atypical ataxia telangiectasia. J Clin Immunol 2012;32(3):438-40.

APA	Haskoloğlu Z, BAL S, ISLAMOĞLU C, BASKIN K, Dogu F, İkincioğulları A, AYTEKIN C, YAVUZ Z, altun d, CEYLANER S (2020). Does the Hyper IgM Phenotype Affect Prognosis in Ataxia Telangiectasia?. , 38 - 46. 10.21911/aai.523
Chicago	Haskoloğlu Zehra Şule,BAL Sevgi KÖSTEL,ISLAMOĞLU Candan,BASKIN Kübra,Dogu Figen,İkincioğulları Aydan,AYTEKIN Caner,YAVUZ ZEYNEP,altun demet,CEYLANER Serdar Does the Hyper IgM Phenotype Affect Prognosis in Ataxia Telangiectasia?. (2020): 38 - 46. 10.21911/aai.523
MLA	Haskoloğlu Zehra Şule,BAL Sevgi KÖSTEL,ISLAMOĞLU Candan,BASKIN Kübra,Dogu Figen,İkincioğulları Aydan,AYTEKIN Caner,YAVUZ ZEYNEP,altun demet,CEYLANER Serdar Does the Hyper IgM Phenotype Affect Prognosis in Ataxia Telangiectasia?. , 2020, ss.38 - 46. 10.21911/aai.523
AMA	Haskoloğlu Z,BAL S,ISLAMOĞLU C,BASKIN K,Dogu F,İkincioğulları A,AYTEKIN C,YAVUZ Z,altun d,CEYLANER S Does the Hyper IgM Phenotype Affect Prognosis in Ataxia Telangiectasia?. . 2020; 38 - 46. 10.21911/aai.523
Vancouver	Haskoloğlu Z,BAL S,ISLAMOĞLU C,BASKIN K,Dogu F,İkincioğulları A,AYTEKIN C,YAVUZ Z,altun d,CEYLANER S Does the Hyper IgM Phenotype Affect Prognosis in Ataxia Telangiectasia?. . 2020; 38 - 46. 10.21911/aai.523
IEEE	Haskoloğlu Z,BAL S,ISLAMOĞLU C,BASKIN K,Dogu F,İkincioğulları A,AYTEKIN C,YAVUZ Z,altun d,CEYLANER S "Does the Hyper IgM Phenotype Affect Prognosis in Ataxia Telangiectasia?." , ss.38 - 46, 2020. 10.21911/aai.523
ISNAD	Haskoloğlu, Zehra Şule vd. "Does the Hyper IgM Phenotype Affect Prognosis in Ataxia Telangiectasia?". (2020), 38-46. https://doi.org/10.21911/aai.523

APA	Haskoloğlu Z, BAL S, ISLAMOĞLU C, BASKIN K, Dogu F, İkincioğulları A, AYTEKIN C, YAVUZ Z, altun d, CEYLANER S (2020). Does the Hyper IgM Phenotype Affect Prognosis in Ataxia Telangiectasia?. Astım Allerji İmmünoloji, 18(1), 38 - 46. 10.21911/aai.523
Chicago	Haskoloğlu Zehra Şule,BAL Sevgi KÖSTEL,ISLAMOĞLU Candan,BASKIN Kübra,Dogu Figen,İkincioğulları Aydan,AYTEKIN Caner,YAVUZ ZEYNEP,altun demet,CEYLANER Serdar Does the Hyper IgM Phenotype Affect Prognosis in Ataxia Telangiectasia?. Astım Allerji İmmünoloji 18, no.1 (2020): 38 - 46. 10.21911/aai.523
MLA	Haskoloğlu Zehra Şule,BAL Sevgi KÖSTEL,ISLAMOĞLU Candan,BASKIN Kübra,Dogu Figen,İkincioğulları Aydan,AYTEKIN Caner,YAVUZ ZEYNEP,altun demet,CEYLANER Serdar Does the Hyper IgM Phenotype Affect Prognosis in Ataxia Telangiectasia?. Astım Allerji İmmünoloji, vol.18, no.1, 2020, ss.38 - 46. 10.21911/aai.523
AMA	Haskoloğlu Z,BAL S,ISLAMOĞLU C,BASKIN K,Dogu F,İkincioğulları A,AYTEKIN C,YAVUZ Z,altun d,CEYLANER S Does the Hyper IgM Phenotype Affect Prognosis in Ataxia Telangiectasia?. Astım Allerji İmmünoloji. 2020; 18(1): 38 - 46. 10.21911/aai.523
Vancouver	Haskoloğlu Z,BAL S,ISLAMOĞLU C,BASKIN K,Dogu F,İkincioğulları A,AYTEKIN C,YAVUZ Z,altun d,CEYLANER S Does the Hyper IgM Phenotype Affect Prognosis in Ataxia Telangiectasia?. Astım Allerji İmmünoloji. 2020; 18(1): 38 - 46. 10.21911/aai.523
IEEE	Haskoloğlu Z,BAL S,ISLAMOĞLU C,BASKIN K,Dogu F,İkincioğulları A,AYTEKIN C,YAVUZ Z,altun d,CEYLANER S "Does the Hyper IgM Phenotype Affect Prognosis in Ataxia Telangiectasia?." Astım Allerji İmmünoloji, 18, ss.38 - 46, 2020. 10.21911/aai.523
ISNAD	Haskoloğlu, Zehra Şule vd. "Does the Hyper IgM Phenotype Affect Prognosis in Ataxia Telangiectasia?". Astım Allerji İmmünoloji 18/1 (2020), 38-46. https://doi.org/10.21911/aai.523